Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556009 · ClinicalTrials.gov registry record · Phase 2
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT01556009: Completed Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT01556009 is a Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 24 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556009, a Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).
Conditions Studied
Interventions
- DRUG Vismodegib
- DRUG Aminolevulinic acid %20 topical solution
Study Locations (3)
California
- Children's Hospital Oakland Research Institiute - Oakland
- Children's Hospital Research Center Oakland - Oakland
New York
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556009
The ClinicalTrials.gov registry entry for NCT01556009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Basal Cell Nevus Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT01556009 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT01556009 about?
NCT01556009 is a clinical study titled "Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas". The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).
What is the current status of trial NCT01556009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2012-04. Estimated completion is 2015-12.
What conditions does trial NCT01556009 study?
This clinical trial studies the following conditions: Basal Cell Nevus Syndrome, Gorlin's Syndrome.
What interventions are being tested in trial NCT01556009?
The interventions under investigation include: Vismodegib (DRUG), Aminolevulinic acid %20 topical solution (DRUG).
Who is sponsoring clinical trial NCT01556009?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01556009 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.